Sankalp Arora, Hematology/Medical Oncology Fellow at MD Anderson Cancer Center, shared in a post on X:
“Sharing our ASCO25 abstract: relapse mechanisms after FLT3i rx in frontline AML.
FLT3 loss and emergent DNA methylation/RAS-MAPK/WT1 mutations were common at relapse. Post SCT relapses were less likely to be driven by emergent mutations.”